Enpath sees FDA delay for steroid-eluting heart pacing lead
This article was originally published in Clinica
Executive Summary
Enpath Medical has expressed disappointment at the FDA's decision that it must provide the agency with prospective human clinical trial data for its steroid-eluting heart pacing lead before the product can be approved in the US.